BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics, Inc., operating as BBOT, is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with cancers driven by RAS and PI3Kα, two of the most frequently mutated oncogenes. Headquartered in South San Francisco, California, the company's mission is to accelerate scientific and medical breakthroughs to deliver well-tolerated, safe, and highly efficacious medicines for individuals facing deadly cancers.

BBOT focuses on developing novel small molecule therapeutics that target RAS and PI3Kα malignancies. Its pipeline includes BBO-8520, a direct KRASG12C inhibitor; BBO-11818, a pan-KRAS inhibitor; and BBO-10203, a RAS:PI3Kα breaker. These product candidates are currently in Phase I clinical trials, addressing various cancers such as lung, breast, colorectal, and pancreatic cancers.

BBOT debuted as a publicly traded company on the NASDAQ Global Market in August 2025, following a business combination with Helix Acquisition Corp. II. Recent corporate developments include multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting in 2026, where the company shared preclinical data on its pipeline programs. In April 2026, the company announced the appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, and Idan Elmelech as Chief Operating Officer.